Cure8 research brief
Researchers are testing whether IL-22 — a cytokine known to help repair gut and airway lining — could protect or heal GI tissues after SARS‑CoV‑2 infection. If true, this could point to therapies relevant to people with IBD-like gut injury after COVID (PASC).
Researchers studying immune pathways or long COVID; clinicians and patients interested in immune-targeted tissue-repair therapies, especially those with IBD or post-COVID GI symptoms.
This is an NIH-funded project proposal studying whether the cytokine IL-22 protects lung and gastrointestinal tissues during SARS-CoV-2 infection and might inform therapies to prevent or treat post-acute sequelae of COVID-19 (PASC).
The team will use in vitro respiratory and GI cell models and an in vivo mouse model to examine IL-22 effects on epithelial proliferation, apoptosis resistance, and tissue repair.
The proposal notes that recombinant IL-22-Fc is already in clinical trials for ulcerative colitis and for tissue repair in acute graft-versus-host disease, and frames the research as addressing a knowledge gap about cytokine roles in PASC and potential for IL-22–targeted therapies.
This summary is based on the NIH Reporter project abstract and terms; it is a project-record summary, not a report of study results.
This is a funded research project proposal (preclinical work in cells and mice); it reports planned experiments rather than clinical results. Recombinant IL-22–Fc is mentioned as being in clinical trials for other conditions, but this project does not present human trial data for COVID or IBD.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Allergy and Infectious Diseases - R21AI193667 - $178,750
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.
The study suggests a probiotic strain (Lactobacillus plantarum) reduced inflammation and prolonged remission in multiple mouse models of Crohn’s-like disease, indicating microbiome-based approaches might be promising to...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
